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Background. A definitive diagnosis of malignant pleural effusion (MPE) is reached by cytological or histological assessment, but
thorough analysis of the ultrasound features of the effusion as well as pleural thickening or nodularity can also be of significant
diagnostic help. Objective. To assess the relationship of specific ultrasound characterisctics and macroscopic features of confirmed
malignant pleural effusion, thus increasing the diagnostic potential of thoracic ultrasound. Methods. The findings of thoracic
ultrasonography performed prior to initial thoracentesis in 104 patients with subsequently confirmed malignant pleural effusion
were analyzed with regard to the macroscopic features of the pleural effusion. Results. Distribution in terms of frequency of
hemorrhagic/sanguinolent (n=64) in relation to nonhemorrhagic transparent/opaque (n=40) MPE, regardless of their ultrasound
characteristics, did not yield a statistically significant correlation (p=0.159). Conversely, the frequency distribution of hemorrhagic
pleural effusions (n=8) in relation to nonhemorrhagic effusions (n=1), in the group of septated MPE, showed a statistically
significant difference (p<0.001).The least number of patients (0.96%) had a complex septatedMPE combined with themacroscopic
appearance of a serous/transparent nonhemorrhagic effusion, which suggests that this combination is a sporadic occurrence and
may have a diagnostic significance for this patient group. Conclusion. The incidence of specific combinations of the ultrasound
characteristics and macroscopic appearance of MPEs showed different frequency distributions, which may improve the diagnostic
value of thoracic ultrasound in this patient population.
1. Introduction
Pleural effusion is a commonmanifestation of various malig-
nancies, suggesting advanced disease and a poor prognosis.
Approximately 30% of malignant pleural effusions originate
from lung carcinoma and result in survival rates of 8-10
months [1]. Detection of pleural effusion often leads to
prompt implementation of standardized diagnostic proce-
dures with thoracocentesis as the initial step.
Thoracic ultrasound (TUS) is an important, often initial,
diagnostic method for the detection and localization of
pleural effusion, as well as for the safe performance of
further invasive diagnostic procedures. Since it enables real-
time visualization, TUS significantly increases diagnostic
accuracy, considerably diminishing the number of potential
complications. A detailed thoracic ultrasound examination
incorporates the analysis of sonographic features of the
effusion, the visceral and parietal pleura, and the visible lung
parenchyma. Although the definitive diagnosis of malignant
effusion ismade froma cytological or histological assessment,
a thorough analysis of the ultrasound findings has significant
diagnostic value.
According to Yang et al. [2], pleural effusion is classified
as anechoic, complex septated, complex nonseptated, or
homogeneously echogenic. The echogenicity of the pleural
effusion is assessed by comparing it with the echogenicity of
the liver (hypoechoic, isoechoic, and hyperechoic), while the
reference value for anechogenicity is the echogenicity of bile
in the gallbladder. The terms “complex” or “heterogeneous”
are used to denote findings of echogenic zones within an
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anechoic effusion. Fibrinous septation is a relatively common
finding in pleural effusion and varies in intensity, ranging
from a few separated, often floating, fibrin strands to dense
reticular structures with a honeycomb appearance [3–5].
Fibrinous septation is the consequence of an increased
amount of proteins in the effusion, therefore being a common
finding in exudates, including tuberculous, pleural empyema,
hematothorax, and parapneumonic effusions [6, 7].
According to Yang et al. [2] transudate pleural effusion
is always anechoic, whereas exudates, both malignant and
nonmalignant, may be anechoic or echogenic. The authors
reported findings of anechoic pleural effusion in 27% of
nonmalignant and 40% of malignant pleural effusions, a
similar distribution of various types of echogenic effusions.
Conversely, Bugalho et al. [7] found only 5% of anechoic
malignant effusions, which is in line with the results of
others [6, 8]. In most cases, the malignant effusion presented
features of complex nonseptated effusion [2].
The potential cause for the lower incidence of fibrinous
septation in malignant effusion has been analyzed at the
molecular level. It was proposed to be the consequence of
increased fibrinolytic activity in malignant effusion resulting
from a higher level of tissue plasminogen activator (tPA).
In contrast, tuberculous exudates were characterized by an
increased level of the inhibitor type-1 of tissue plasminogen
activator (PAI -1) and tumor necrosis factor alpha (TNF-
alpha) [9, 10].The fibrinous septation was also reported to be
a consequence of repeated thoracocenteses and pleurodesis,
where increased levels of inflammatory cytokines (TNF-
alpha, IL-1, IL-5, IL-6, and IL-8) were found [11, 12].
Malignant pleural effusion has biochemical features of
exudate and only rarely presents as transudate [13, 14].
Macroscopically, malignant pleural effusions can be serous,
sanguinolent, or hemorrhagic. Cytological analysis reveals
predominance of lymphocytes, macrophages, and mesothe-
lial cells, whereas there are usually less than 25% of polymor-
phonuclears and between 8 and 12%of eosinophils [15] found.
A complete chest sonography includes an estimate of
pleural thickness, possible detection of pleural nodes, and
an examination of the adjacent lung parenchyma (presence
of the air bronchogram or possible pulmonary consolida-
tion). TUS also enables measurement of the thickness of
the diaphragm, as well as the possible detection of liver
metastases. Although the finding of the thickened visceral,
parietal, and diaphragmal pleura is common in malignant
effusions, if it is less than 1 cm, it does not have specific diag-
nostic relevance [7, 8]. On the contrary, pleural thickening
greater than 1 cm, along with the finding of pleural nodes,
is very indicative. Bugalho et al. [7] reported these findings
in 79% of malignant and only 9% of nonmalignant pleural
effusions. The presence of air bronchogram is more common
in nonmalignant effusions.
As proof of malignant etiology, cytological analysis of
the pleural effusion sampled at initial thoracocentesis has
a sensitivity of 62%. The repeated procedures increase the
sensitivity up to 72% (49-91%) [16]. This indicates that for
a large number of patients further diagnostic evaluation
is necessary. Targeted TUS-guided pleural biopsy increases
the number of successfully diagnosed malignant effusions
with sensitivity of almost 90% [17–19]. However, in the
case of some pleural effusions collected in patients with
lung carcinoma, the presence of malignant cells or pleural
involvement cannot be detected. Such cases are classified
as paramalignant pleural effusions resulting from diverse
causes, including atelectasis, pulmonary embolism, hypoal-
buminemia, chylothorax, radiotherapy, and chemotherapy
[20].
The objective of our study was to assess the relationship of
specific ultrasound characterisctics and macroscopic features
of confirmed malignant pleural effusion, thus increasing the
diagnostic potential of thoracic ultrasound.
2. Materials and Methods
This retrospective, single-center study was conducted at
the Division of Pulmonology of the University Hospital
Dubrava in Zagreb, Croatia, during a 4-year period (January
2014–June 2018). It has been approved by the institutional
Ethics Committee.
2.1. Subjects. The studied subjects were selected among
patients referred for thoracic ultrasonography because of
suspected pleural effusion at the standard chest X-ray. In
the studied group of patients, the malignant etiology of effu-
sion was subsequently established using regular diagnostic
procedures. This means that, in case of repeatedly negative
cytoanalysis of effusion, ultrasound- or CT-guided pleural
needle biopsy was performed. A few patients underwent
video-assisted thoracoscopy (VATS) with biopsy of the pleura
and/or lung parenchyma. All collected samples were analyzed
at the Department of Cytology and Pathology in the same
institution. Patients with contraindications for thoracentesis
and those who did not give their consent to participate in the
study were excluded.
2.2. Ultrasonography. The procedure was performed using
the Aloka 7 Utrasound System (Aloka, Japan). A 2-5 MHz
convex probewas used for the analysis of the pleural effusion,
visceral pleura, and lung parenchyma, whereas the parietal
pleura and thoracic wall were examined with the use of a
linear 5-10MHz probe.The examination was conducted with
the patient placed in the sitting position, by a pulmonologist
experienced in the use of TUS (15Y). The thoracic cavity was
systematically examined by moving the probe from dorsal to
ventral along the intercostal spaces from the diaphragm to the
lung apices.
Based on the ultrasound features, the pleural effu-
sions were classified as anechoic, homogeneously echogenic,
complex septated, or complex nonseptated. Furthermore,
the appearance and thickness of the parietal, visceral, and
diaphragmal pleura were analyzed, as well as the avail-
able lung parenchyma and the thoracic wall structures.
After ultrasonography, ultrasound-guided pleural puncture
was performed in accordance with the British Thoracic
Society (BTS) guidelines [20]. The gross features of the
obtained samples (transparent clear to pale yellow, pale yel-
lowwith cloudy appearance, opaque, sanguinolent, and hem-
orrhagic) were recorded, before the samples were referred
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Table 1: Primary origin and type of malignant disease in patients
with malignant pleural effusion.
Site and type of tumor Patients (N)
Lung adenocarcinoma 34
Small cell lung carcinoma 5
Non-small cell lung carcinoma 4
Pleural mesothelioma 6
Gastric adenocarcinoma 9
Colon adenocarcinoma 16
Invasive ductal breast cancer 14
Ovarian carcinoma 4
Endometrial carcinoma 2
Thymic carcinoma 1
Papillary carcinoma of the urinary bladder 1
Melanoma 2
Non-Hodgkin lymphoma 5
Acute myeloid leukemia 1
for further biochemical, microbiological, and cytologocal
assessment.
2.3. Statistical Analysis. The collected data were entered into
the Excel spreadsheet (MS Office 2007) and the cumulative
frequency for the ultrasound features and gross findings of
the malignant pleural effusions was calculated. Statistical
analysis of the frequency table was done by Chi-square
test, using the SAS Studio 3.5 statistical software package
(SAS Institute Inc., Cary, NC, USA). P<0.05 was considered
statistically significant.
3. Results
In the above-mentioned 4-year period, 104 patients (55
females, 49 males, mean age 69 years) with confirmed
MPE were recorded by means of retrospective analysis. The
malignant nature of the effusionwas confirmed by the finding
of malignant cells in pleural effusion samples from 72 (69%)
patients, in transthoracic pleural biopsy samples from 26
(25%) patients, and in samples obtained by surgical pleural
biopsy during VATS from 6 (6%) patients. In 97 patients the
pleural effusion was a result of solid tumor metastasis, while
7 patients had a dissemination of hematologic disease. In the
majority of the cases, the primary sites of the tumors were the
lungs (41%), organs of the gastrointestinal tract (24%), and
the breasts (13%). Table 1 lists the primary sites as well as the
types of tumors and hematologic diseases diagnosed in the
patients with MPEs.
Based on the ultrasound features, 95 (91.35%) patients
had a nonseptated pleural effusion (in 11 patients the pleu-
ral effusion was classified as anechoic, in 16 patients as
homogeneously echogenic, and in 68 patients as complex
nonseptated), and 9 (8.65%) patients were found to have
a septated pleural effusion. Table 2 lists the ultrasound
characteristics of the MPEs as well as their gross features.
Figure 1 shows the typical ultrasound finding of fibrinous
Figure 1: Typical ultrasonographic image of malignant pleural
effusion with fibrinous septation. Fibrin strands within a pleural
effusion can be seen (white arrows); E = pleural effusion.
Figure 2: Typical ultrasonographic image of complex nonseptated
malignant pleural effusion. Heterogeneously hyperechoic spots
inside effusion (right white arrow) without fibrinous septations can
be seen. D = diaphragm (left bold white arrow); E = pleural effusion.
septations in a complex septated pleural effusion, and in
Figure 2 a complex nonseptated pleural effusion can be seen.
According to the macroscopic characteristics, in 64
patients (62%) pleural effusion was sanguinolent/hemor-
rhagic, in 15 patients (14%) transparent and clear, while in the
remaining 25 patients (24%) the effusion was pale yellowwith
cloudy appearance or opaque. The frequency distribution of
the hemorrhagic/sanguinolent (n=64) in comparison with
the nonhemorrhagic transparent or cloudy/opaque MPEs
(n=40), regardless of their ultrasound characteristics, did not
yield a statistically significant correlation (p=0.159).
The frequency distribution of the septated (n=8) in
relation to the nonseptated pleural effusions (n=56) within
the group of hemorrhagic effusions showed a statistically
significant difference (p=0.0001).
In view of the specific ultrasound findings, special atten-
tion was given to the analysis of pleural effusions with
fibrinous septations. Out of the 9 patients with MPEs with
fibrinous septations, 3 had metastasis originating from lung
tumors, in 2 cases the primary malignancies were adenocar-
cinomas of the lung, and there was one case of small cell
lung carcinoma. Out of the remaining 6 complex septated
pleural effusions, three were caused by the propagation of
solid extrathoracic tumors (gastric carcinoma, melanoma,
and papillary urinary bladder carcinoma), and 3 were the
result of malignant hematologic disease dissemination (non-
Hodgkin lymphoma and acute myelogenous leukemia). In 8
4 Pulmonary Medicine
Table 2: Ultrasound features and macroscopic appearance of malignant pleural effusions.
Ultrasound characteristic Macroscopic finding
Sanguinolent/ hemorrhagic Serous transparent Serous opaque
n % n % n % n % n %
Complex septated 9 8.65 9 8.65 8 88.89 1 11.11 0 0.00
Homogeneously echogenic 16 15.39
95 91.35 56 58.95 14 14.74Anechoic 11 10.58 25 26.31
Complex non-septated 68 65.38
Total 104 100.00 104 100.00
patients from this group the pleural effusion was sanguino-
lent or hemorrhagic, and only one patient (non-Hodgkin
lymphoma) had a transparent serous pleural effusion.The fre-
quency distribution of hemorrhagic pleural effusions (n=8)
as compared to nonhemorrhagic effusions (n=1), within
the group of MPEs with fibrinous septations, showed a
statistically significant difference (p<0.0001). From the data
listed in Table 2 it can be concluded that the combination
of a macroscopically nonhemorrhagic pleural effusion and
fibrinous septations was a sporadic occurrence in the MPE
group, found only in one of the 104 patients.
Pleural nodularity was established in 53 patient sam-
ples, 75% of which were macroscopically hemorrhagic/san-
guinolent. Pleural thickening (>10 mm) was confirmed in
45 patients, 64% of which had gross features of hemor-
rhagic/sanguinolent pleural effusion.
The majority of the analyzed pleural effusions were
lymphocytic (>50% lymphocytes). The number of poly-
morphonuclears was lower than 25%, and the amount of
eosinophils was less than 12%. In 3 (3%) patients the malig-
nant pleural effusion had transudate characteristics.
4. Discussion
This is the first study to compare themacroscopic characteris-
tics with the ultrasound findings inMPE. Consistent with the
results of other authors [21, 22], distribution analysis of the
macroscopic findings in MPE, regardless of the ultrasound
features, did not yield a statistically significant difference
(p=0.159). Yang et al. [2] were the first to describe the
ultrasound characteristics of MPE, whereas Qureshi et al. [8]
repoted that malignancies had been diagnosed by TUS in
26/33 patients. Out of 7 false-negative results, the CT findings
were negative in 6 (86%) patients. The authors concluded
that ultrasound findings of pleural nodularity accompanied
by a thickening of the parietal costal pleura by >10 mm and
the diaphragmatic pleura by >7 mm represented a significant
predictor of a malignant etiology of the pleural effusion, with
a procedure sensitivity of 73% and a specificity of 100%. It
has to be emphasized that pleural nodularity was confrmed
in specific pleural effusions as well [7]. Due to that fact,
the finding of pleural nodularity is not considered pathog-
nomonic for MPE, especially in regions where tuberculosis
is common, although it still remains a significant predictor
of malignancy in undiagnosed pleural effusion (sensitivity
78.8%, specificity 91.0%). In our patient cohort pleural
nodularity was established in 51% of the cases. In 75% of
these patients the effusion was hemorrhagic or sanguinolent.
Consistent with that, a >10 mm thickening of the parietal
pleurawas confirmed in 43%of the patients, out of which 56%
had a hemorrhagic or sanguinolent effusion. Furthermore,
the literature describes two more ultrasound findings, i.e.,
the invasion of thoracic wall structures and the presence of
liver metastasis, which suggest a malignant etiology of the
pleural effusion with a high sensitivity and specificity [7, 23].
These ultrasound criteria are present in a smaller number of
MPE patents. Negative cytological findings combined with
ultrasound criteria which suggest a malignant etiology of
the pleural effusion require a further diagnostic workup and
obtaining samples for pathohistological analysis.
Two further ultrasound characteristics with a higher
incidence in MPE in relation to nonmalignant pleural
effusion (NMPE) are the absence of air bronchograms in
the peripheral lung infiltrate (p=0.001) and the absence of
fibrinous septations in the pleural effusion (p=0.006) [7].The
cited parameters display a high sensitivity, but low specificity.
The absence of air bronchograms has a sensitivity of 92.4%
and a specificity of 31.3% [7]. False-negative findings are most
often due to malignant obstructive pneumonia. Fibrinous
sepations are a relatively rare finding in MPE, reported by
various authors at an incidence of 4-7.5% [6–8]. TUS is a very
reliable method for the assessment of septations in pleural
effusion, with a sensitivity of 92.4% [7]. However, due to its
low specificity (25%), the analysis of fibrinous septations has
a limited diagnostic value. The possibility of errors in the
ultrasound evaluation of fibrinous septations in the effusion
needs to be taken into account. This applies to the findings of
floating visceral pleura of an atelectatic lung lobe (Figure 3)
and pleural adhesions (Figure 4), which are common in
effusions with transudate features that have been present for
a longer period of time.They are usually supradiaphragmatic,
with cytological features of reactively changed, macrophage-
transformed mesothelial cells [24].
Taking into account the results of studies conducted
so far, and with the aim of improving the effectiveness
of TUS in MPE patients, macroscopic findings of pleural
effusion were analyzed retrospectively within the context
of their ultrasound characteristics. Upon statistical analysis
and the correlation of frequency distributions of specific
combinations of macroscopic appearance and ultrasound
characteristics ofMPEs, significant results were obtained.The
frequency distribution of hemorrhagic/sanguinolent (n=64)
in relation to nonhemorrhagic transparent/opaque (n=40)
malignant pleural effusions, regardless of their ultrasound
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Figure 3: Floating visceral pleura due to atelectasis of the lung lobe
(right white arrow). D = diaphragm (left bold white arrow); E =
pleural effusion.
Figure 4: Pleural adhesions. Pleural adhesions (right white arrow)
with sharp contours, hyperechoic, connecting the diaphragmatic
pleura and parenchyma of the collapsed lung. D = diaphragm (left
bold white arrow); E = pleural effusion.
characteristics, did not yield a statistically significant corre-
lation (p=0.159). In contrast, the frequency distribution of
hemorrhagic (n=8) as compared to nonhemorrhagic pleu-
ral effusions (n=1), within the group of malignant pleural
effusions with fibrinous septations, showed a statistically sig-
nificant difference (p<0.0001). The least number of patients
(0.96%) had a complex septated MPE combined with the
macroscopic appearance of a serous/transparent nonhemor-
rhagic effusion, which suggests that this combination is a
sporadic occurrence and may have a diagnostic significance
for this patient group.
The authors are aware of the study limitations, particu-
larly in view of the fact that it was a retrospective investigation
which did not include patients with nonmalignant pleural
effusion. We believe that prospective study, which would
also include patients with nonmalignant pleural effusion,
would help in better evaluation of diagnostic value of tho-
rasis ultrasound in the assessment of malignant etiology in
undiagnosed pleural effusions.
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